Because of the fast-progression of zone I type 1 ROP and A-ROP, if the initial treatment could not control ROP in time, the rate of progression to retinal detachment in the anti-VEGF agent group was 10%, significantly lower than that (22%) in the laser group (P = 0.001). The gene discussed is VEGFA; the disease is retinal detachment.